查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984059

下一代肿瘤治疗设备和解决方案市场：按设备类型、技术、癌症类型和最终用户划分－2026-2032年全球市场预测

Next-Generation Oncology Devices & Solutions Market by Device Type, Technology, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，下一代肿瘤设备和解决方案市场价值将达到 230.5 亿美元，到 2026 年将成长至 280.2 亿美元，到 2032 年将达到 911.8 亿美元，复合年增长率为 21.70%。

主要市场统计数据
基准年 2025 230.5亿美元
预计年份：2026年 280.2亿美元
预测年份 2032 911.8亿美元
复合年增长率 (%) 21.70%

肿瘤医疗设备及解决方案市场正迈入一个以技术融合、临床精准和持续推进以病人为中心的工作流程为特征的新时代。分子诊断、影像学和医疗设备自动化技术的进步正推动肿瘤治疗从间歇性干预转向持续的、数据驱动的管理。因此，临床路径正在重组，以将早期检测、更精准的肿瘤表征和适应性治疗纳入常规实践。这种变革并非局限于单一技术领域，而是涵盖诊断、影像、监测、手术和治疗性医疗设备等各个方面，所有这些技术协同运作，共同建构封闭回路型肿瘤治疗系统。

从概念验证(PoC) 过渡到广泛的临床部署，需要製造、监管策略、报销途径和医疗采购结构等方面的协调一致。相关人员必须应对日益增长的临床证据期望、与医疗资讯科技系统的互通性以及与医疗团队的无缝整合等挑战。因此，最成功的机构将是那些能够将严格的临床检验、切实可行的商业化计划、对医疗服务提供者工作流程的深刻洞察以及向支付方和医疗系统展示实际价值的能力结合起来的机构。

新兴的人工智慧、基因组学、影像技术和微创技术如何融合，重新定义肿瘤治疗的临床路径和经营模式。

临床实践的根本性转变、技术的成熟以及策略市场趋势正在加速整个肿瘤医疗设备生态系统的转型。人工智慧和先进的分析技术不再是小众功能，而是能够提高诊断成像准确性、简化病理工作流程以及在治疗方法选择中优先考虑基因组分析结果的实用工具。同时，次世代定序和数位病理正在缩短诊断时间，并支持多模态数据的整合，从而帮助精准医疗。

评估关税政策变化对全球供应链、医疗设备设计、监管合规性和癌症治疗技术整体趋势的策略性影响。

美国2025年实施的关税措施为肿瘤医疗设备及解决方案领域的企业带来了新的营运和策略考量。在製造层面，进口零件和组件成本的增加影响了成本结构，促使企业重新评估全球筹资策略。许多製造商正在探索近岸外包、双重采购和本地化供应商网路等策略，以降低关税带来的成本波动风险。因此，供应链设计正从单纯的成本优化转向以韧性为中心的模式，强调时间把控、库存策略和合约柔软性。

透过对医疗设备、技术、癌症类型和最终用户细分进行详细分析，我们将揭示整个肿瘤护理领域不同的发展重点和采用趋势。

精准理解细分市场对于探索肿瘤医疗设备的产品开发重点和商业化路径至关重要。医疗设备的分类包括诊断系统（如免疫组织化学和萤光杂合反应(FISH)）、分子平台（如聚合酵素链锁反应(PCR)，包括数位 PCR 和定量 PCR）以及次世代定序(NGS)（涵盖EXOME序、标靶基因组定序和全基因组定序）。影像技术涵盖了从锥状射束和多切面配置的电脑断层扫描 (CT) 平台到 1.5T 和 3T 磁场强度的磁振造影(MRI) 系统，以及正子断层扫描 (PET) 解决方案（PET/CT 或 PET/MRI 混合型）。超音波诊断设备从传统的二维成像到先进的3D和四维成像功能不等，而 X 光系统则包括电脑放射成像 (CR)数位放射线(DR)。监测解决方案越来越多地利用生物感测器和穿戴式装置来实现时间序列资料收集。同时，外科手术工具包括冷冻手术、腹腔镜手术技术和机器人平台，以支援精准手术。治疗设备产品组合涵盖药物传输系统和放射治疗方式，其中放射治疗解决方案包括近距离放射系统、线性加速器和质子治疗设备。

区域比较分析揭示了法律规范、临床基础设施和製造地如何影响肿瘤设备的引进和市场发展。

区域趋势对肿瘤医疗设备和解决方案的监管预期、部署计画和商业化路径有显着影响。在美洲，整体的临床试验基础设施、众多专业癌症中心以及日益重视临床和经济价值证据的支付方环境，正在加速创新诊断和医疗设备的普及应用。该地区也是医疗设备製造和风险投资的中心，这不仅支持了快速的商业化週期，也对强有力的上市后监测和真实世界数据（RWE）的生成提出了更高的要求。

现有平台、专业创新者和策略合作伙伴正在透过整合解决方案、智慧财产权定位和服务主导的差异化重新定义竞争格局。

肿瘤领域医疗设备和解决方案的竞争格局呈现出多元化的特点，既有大规模平台供应商，也有专注于临床创新、技术领先的Start-Ups公司。成熟的医疗科技公司正利用其广泛的销售管道、服务网路和监管经验，拓展硬体、软体和服务相结合的整合解决方案。同时，一些专注于特定领域的公司在分子诊断、数位病理学和机器人等领域不断涌现颠覆性技术，迫使成熟公司寻求伙伴关係、授权协议或进行有针对性的收购，以保持其临床竞争力。

为高阶主管提供可操作的策略挑战，以加强供应链、证据产生、产品模组化和经营模式，从而确保可持续的竞争优势。

产业领导企业必须采取多管齐下的策略来降低系统性风险，同时抓住下一代肿瘤医疗设备所带来的机会。首先，供应链韧性应成为一项策略重点。供应商多元化、尽可能投资近岸製造以及重新设计产品以适应组件的柔软性，都能降低政策引发的干扰风险。同时，企业应优先产生符合支付方要求和医疗采购标准的可靠临床和卫生经济学证据。儘早与临床医生、卫生技术评估机构和支付方决策者合作，将有助于试验设计和资料收集更精准地聚焦于最相关的终点指标。

透过结合专家访谈、监管和临床证据审查以及多方面的资讯匹配，我们确保获得可靠且可操作的见解。

本分析所依据的研究采用了一种多层次的调查方法，旨在确保研究的严谨性、多方验证以及与相关人员的相关性。主要研究包括对意见领袖、采购负责人、监管专家以及医疗设备製造商和医院系统的管理人员进行结构化访谈。此外，还透过系统性地查阅公开的监管文件、临床试验註册信息、同行评审文献和专利资讯披露，补充了这些定性信息，以识别技术进步和证据缺口。同时，透过分析公司新闻稿、产品公告和投资者报告，检验了市场和技术趋势，以了解策略意图和资源分配。

摘要重点强调综合临床平台、实证商业化以及对政策和区域差异的适应能力。

总而言之，下一代肿瘤医疗设备和解决方案将由整合高精度诊断、先进影像、智慧软体和微创治疗的平台定义，并最终形成一致的临床路径。能够将卓越的工程技术与临床证据、监管前瞻性和灵活的商业模式相结合的机构将取得成功。关税政策的变化、区域监管差异以及支付方期望的改变等外部因素将继续影响策略选择，并进一步凸显对适应性价值炼和基于价值的定价方法的需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 下一代肿瘤治疗设备和解决方案市场：按设备类型划分

  • 诊断设备
    • 萤光原位杂合反应
    • 免疫组织化学
    • 次世代定序
      • EXOME定序
      • 目标面板
      • 全基因测序
    • 聚合酵素链锁反应
      • 数位PCR
      • 定量PCR
  • 医疗影像设备
    • 电脑断层扫描
      • 锥状射束CT
      • 多切面CT
    • 磁振造影
      • 1.5T 影像诊断
      • 3T成像
    • 正子断层扫描
      • PET/CT混合
      • PET/MRI混合
    • 超音波影像
      • 二维成像
      • 3D/4D成像
    • X光影像诊断
      • 电脑放射成像
      • 数位放射线摄影
  • 监控设备
    • 生物感测器
    • 穿戴式装置
  • 手术器械
    • 冷冻手术
    • 腹腔镜手术
    • 机器人手术
  • 治疗设备
    • 药物输送装置
    • 放射治疗设备
      • 近距离放射治疗系统
      • 直线加速器
      • 质子束治疗系统

第九章 下一代肿瘤设备和解决方案市场：按技术划分

  • 人工智慧
    • 数据分析
    • 深度学习
    • 机器学习
  • 生物资讯学
    • NGS数据分析
    • 蛋白质体学数据分析
  • 数位病理学
    • 影像分析软体
    • 全幻灯片成像
  • 奈米科技
    • 奈米载体
    • 奈米诊断
  • 机器人技术
    • 切片检查机器人
    • 手术机器人

第十章 按癌症类型分類的下一代肿瘤设备和解决方案市场

  • 乳癌
  • 结肠癌
  • 肺癌
  • 摄护腺癌

第十一章 下一代肿瘤设备和解决方案市场：按最终用户划分

  • 门诊部
  • 诊断检查室
  • 医院
  • 研究机构

第十二章 下一代肿瘤设备和解决方案市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 下一代肿瘤设备和解决方案市场：按组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 下一代肿瘤设备和解决方案市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国下一代肿瘤设备与解决方案市场

第十六章：中国下一代肿瘤设备与解决方案市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Brainlab
  • Danaher Corporation
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Guardant Health Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • Novartis AG
  • Paige.AI, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Royal Philips
  • Siemens AG
  • Sysmex Corporation
  • Takara Bio USA, Inc.
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-2E76C3E47F6D

The Next-Generation Oncology Devices & Solutions Market was valued at USD 23.05 billion in 2025 and is projected to grow to USD 28.02 billion in 2026, with a CAGR of 21.70%, reaching USD 91.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.05 billion
Estimated Year [2026] USD 28.02 billion
Forecast Year [2032] USD 91.18 billion
CAGR (%) 21.70%

The oncology devices and solutions landscape is entering an era defined by technological convergence, clinical precision, and a relentless drive toward patient-centered workflows. Advances in molecular diagnostics, imaging modalities, and device automation are moving oncology care from episodic intervention toward continuous, data-driven management. As a result, clinical pathways are being reconfigured to embed earlier detection, more accurate tumor characterization, and adaptive therapeutic delivery in routine practice. This evolution is not limited to a single technology class; instead, it spans diagnostic, imaging, monitoring, surgical, and therapeutic devices that together enable closed-loop oncologic care.

Transitioning from proof of concept to widespread clinical adoption requires alignment across manufacturing, regulatory strategy, reimbursement pathways, and institutional procurement. Stakeholders must navigate heightened expectations for clinical evidence, interoperability with health IT systems, and seamless integration into care teams. Consequently, the most successful organizations will be those that combine rigorous clinical validation with pragmatic commercialization plans, an acute sensitivity to provider workflows, and an ability to demonstrate real-world value to payers and health systems.

How emerging AI, genomics, imaging, and minimally invasive technologies are converging to redefine clinical pathways and commercial models in oncology care

Fundamental shifts in clinical practice, technology maturation, and strategic market behavior are collectively accelerating transformation across the oncology device ecosystem. Artificial intelligence and advanced analytics are no longer niche capabilities; they are operational tools that enhance image interpretation, streamline pathology workflows, and prioritize genomic findings for treatment selection. Concurrently, next-generation sequencing and digital pathology are reducing diagnostic turnaround times and enabling multi-modal data synthesis that supports precision medicine.

In parallel, imaging systems have evolved to offer higher resolution, hybrid modalities, and quantitative biomarkers that improve lesion characterization and response assessment. Wearable biosensors and continuous monitoring platforms are transforming patient engagement and enabling remote assessment of therapy tolerability. Surgical robotics and minimally invasive techniques are refining procedural accuracy while reducing recovery time. Taken together, these shifts are changing how oncology care is delivered, financed, and measured, with implications for clinical workflows, capital allocation, and the competitive landscape.

Assessing the strategic consequences of tariff policy shifts on global supply chains, device design, regulatory compliance, and pricing dynamics across oncology technologies

The implementation of United States tariffs in 2025 has introduced a new set of operational and strategic considerations for companies involved in oncology devices and solutions. At the manufacturing level, cost structures have been affected by increased expenses for imported components and subassemblies, which in turn has encouraged a reassessment of global sourcing strategies. Many manufacturers are evaluating nearshoring, dual-sourcing, and localized supplier networks to mitigate exposure to tariff-driven cost volatility. As a consequence, supply chain design has shifted from a pure cost-optimization focus to a resilience-centric model that emphasizes timing, inventory strategies, and contractual flexibility.

Beyond procurement, tariffs have accelerated redesign efforts for device architecture and bill-of-material simplification. Engineering teams are seeking modular designs that reduce reliance on tariff-sensitive components and prioritize standardized interfaces to enable alternative sourcing. Regulatory affairs and quality teams are also adapting, as component substitutions and supplier changes require timely documentation and revalidation to maintain compliance. On the commercial front, pricing negotiations with health systems and group purchasing organizations have become more complex, with manufacturers needing to substantiate cost increases through transparent total cost of ownership narratives and value-based contracting approaches. Finally, investors and corporate strategists are reassessing capex plans and M&A activity to capture supply chain efficiencies, secure intellectual property, and shore up manufacturing footprints in jurisdictions that reduce tariff exposure.

Unpacking device, technology, cancer type, and end user segmentation to reveal differentiated development priorities and adoption dynamics across oncology care

A nuanced understanding of segmentation is essential to navigate product development priorities and commercialization pathways across oncology devices. Device classifications span diagnostic systems such as immunohistochemistry and fluorescence in situ hybridization, molecular platforms including polymerase chain reaction with digital and quantitative PCR formats, and next-generation sequencing which itself encompasses exome sequencing, targeted panels, and whole genome sequencing approaches. Imaging technologies range from computed tomography platforms with cone beam and multi-slice configurations to magnetic resonance imaging systems offered in 1.5T and 3T field strengths, alongside positron emission tomography solutions available as PET/CT and PET/MRI hybrids. Ultrasound offerings vary from conventional two-dimensional imaging to advanced three-dimensional and four-dimensional capabilities, while X-ray systems exist in computed radiography and digital radiography forms. Monitoring solutions increasingly incorporate biosensors and wearable devices to enable longitudinal data capture, whereas surgical tools include cryosurgery, laparoscopic techniques, and robotic platforms that support precision interventions. Therapeutic device portfolios cover drug delivery systems and radiation therapy modalities, with radiation solutions spanning brachytherapy systems, linear accelerators, and proton therapy installations.

Technology-driven segmentation further clarifies adoption pathways and investment focus. Artificial intelligence is being applied through data analytics, deep learning, and machine learning to enhance diagnostic yield and operational efficiency. Bioinformatics capabilities are centered on next-generation sequencing data analysis and proteomics pipelines, while digital pathology investments emphasize image analysis software and whole slide imaging platforms. Nanotechnology development includes nanocarriers for targeted delivery and nanodiagnostics to improve sensitivity, and robotics continues to differentiate into biopsy-specific systems and surgical robotics optimized for oncology workflows. Clinical focus across cancer types-such as breast, colorectal, lung, and prostate cancers-affects diagnostic and therapeutic priorities, and end-user segmentation encompassing ambulatory care centers, diagnostic laboratories, hospitals, and research institutes determines procurement cycles, IT integration needs, and evidence requirements for adoption. Synthesizing these layers of segmentation enables product teams and commercial leaders to target feature sets, clinical validation plans, and service models that align with distinct clinical and institutional buyer needs.

Comparative regional analysis revealing how regulatory frameworks, clinical infrastructure, and manufacturing footprints influence oncology device adoption and market pathways

Regional dynamics exert a powerful influence on regulatory expectations, adoption timelines, and commercialization pathways across oncology devices and solutions. In the Americas, strong clinical trial infrastructure, a concentration of specialized cancer centers, and payer environments that increasingly reward evidence of clinical and economic value combine to accelerate uptake of innovative diagnostics and devices. This region also remains a focal point for device manufacturing and venture investment, which supports rapid commercialization cycles while demanding robust post-market surveillance and real-world evidence generation.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization initiatives coexist with country-specific reimbursement processes and procurement behaviors. In some markets, centralized approvals and value-based procurement mechanisms encourage cross-border adoption, whereas resource constraints in other jurisdictions necessitate cost-effective, scalable solutions. The region's complex reimbursement tapestry and diverse clinical practice patterns place a premium on modular product models and flexible commercial strategies. Asia-Pacific exhibits a blend of high-volume markets with fast technology adoption, alongside growing local manufacturing capability and strategic public investments in precision medicine. Regulatory authorities in key Asia-Pacific markets are increasingly receptive to expedited pathways for devices demonstrating strong clinical utility, and regional manufacturers are becoming competitive suppliers for global supply chains. Across all regions, adoption is shaped by local workforce capacity, digital infrastructure maturity, and national policy priorities that support early detection, patient access, and cancer research.

How incumbent platforms, focused innovators, and strategic collaborations are redefining competition through integrated solutions, IP positioning, and service-driven differentiation

The competitive landscape in oncology devices and solutions is defined by a mix of large platform providers, specialized technology companies, and agile startups that bring focused innovations to clinical practice. Established medical technology firms leverage broad commercial channels, service networks, and regulatory experience to scale integrated solutions that combine hardware, software, and servicing. Meanwhile, niche companies often advance disruptive capabilities in areas such as molecular diagnostics, digital pathology, and robotics, forcing incumbents to pursue partnerships, licensing agreements, or targeted acquisitions to retain clinical relevance.

Strategic collaborations between device manufacturers, software companies, and clinical research organizations are increasingly common as firms seek to assemble end-to-end value propositions. Intellectual property portfolios centering on algorithms, device interfaces, and component designs serve as key differentiators, while manufacturing scale and supplier relationships underpin cost competitiveness. Moreover, a growing number of companies are expanding offerings beyond product delivery to include data services, clinical decision support, and lifecycle management, thereby creating recurring revenue streams and deeper customer engagement. For commercial teams, understanding competitor positioning across evidence generation, reimbursement support, and aftermarket services is critical to crafting winning value propositions.

Actionable strategic imperatives for executives to strengthen supply chains, evidence generation, product modularity, and commercial models to secure lasting competitive advantage

Industry leaders must adopt a multi-dimensional approach to capture the opportunities presented by next-generation oncology devices while mitigating systemic risks. First, supply chain resilience should be elevated to strategic priority status; diversifying suppliers, investing in near-shore manufacturing where feasible, and redesigning products for component flexibility will reduce exposure to policy-driven disruptions. Simultaneously, companies should prioritize the generation of robust clinical and health economic evidence that aligns with payer requirements and institutional procurement criteria. Early engagement with clinicians, health technology assessment bodies, and payer decision-makers ensures that trial designs and data collection address the most relevant endpoints.

Product strategy should emphasize interoperability, modularity, and software-enabled upgrade paths to extend product lifecycles and support incremental feature deployment. Commercial teams need to craft pricing and contracting models that align provider incentives, including outcomes-based agreements where appropriate, and to build commercial capabilities that support complex sales cycles within hospitals and research institutes. Investing in post-market data capture and real-world evidence platforms not only strengthens regulatory and reimbursement dossiers but also supplies actionable insights for iterative product improvement. Finally, organizational priorities should include talent strategies that attract clinical, regulatory, and digital expertise, and a culture that values rapid evidence-driven iteration to keep pace with clinical innovation.

Methodological framework combining expert interviews, regulatory and clinical evidence review, and multi-source triangulation to ensure robust and actionable insights

The research underpinning this analysis relied on a layered methodology intended to ensure rigor, triangulation, and relevance to stakeholders. Primary research included structured interviews with clinical opinion leaders, procurement professionals, regulatory experts, and senior executives across device manufacturers and hospital systems. These qualitative inputs were complemented by a systematic review of publicly available regulatory filings, clinical trial registries, peer-reviewed literature, and patent disclosures to identify technology trajectories and evidence gaps. Market and technology signals were further validated through analysis of company press releases, product launch materials, and investor presentations to capture strategic intent and resource allocation.

Quantitative analysis was supported by dataset integration and cross-validation routines to ensure consistency across sources. Where appropriate, sensitivity analyses and scenario testing were used to explore implications under different regulatory or policy environments. Throughout the process, quality controls included methodological rubrics for source weighting, peer review by domain experts, and ethical safeguards to protect interview confidentiality. Limitations of the research were acknowledged and addressed by seeking diverse viewpoints across geographies, technology maturity levels, and institutional contexts, ensuring that conclusions are robust and actionable for decision-makers.

Concluding synthesis emphasizing integrated clinical platforms, evidence-driven commercialization, and resilience in the face of policy and regional variability

In summary, the next wave of oncology devices and solutions will be defined by platforms that integrate high-fidelity diagnostics, advanced imaging, intelligent software, and minimally invasive therapeutics into coherent clinical pathways. Success will favor organizations that can harmonize engineering excellence with clinical evidence, regulatory foresight, and flexible commercial models. External forces such as tariff policy shifts, regional regulatory variability, and evolving payer expectations will continue to shape strategic choices, reinforcing the need for adaptable supply chains and value-based pricing approaches.

Stakeholders that proactively align product strategies with clinical workflows, invest in real-world evidence generation, and cultivate partnerships across the ecosystem will be best positioned to accelerate adoption and realize the promise of precision oncology. Conversely, firms that maintain siloed development, under-invest in post-market data, or fail to anticipate policy-driven cost pressures risk slower uptake and margin compression. The path forward requires disciplined execution, cross-functional coordination, and a relentless focus on demonstrating tangible clinical and economic value to patients, providers, and payers alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Oncology Devices & Solutions Market, by Device Type

  • 8.1. Diagnostic Devices
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Immunohistochemistry
    • 8.1.3. Next Generation Sequencing
      • 8.1.3.1. Exome Sequencing
      • 8.1.3.2. Targeted Panels
      • 8.1.3.3. Whole Genome Sequencing
    • 8.1.4. Polymerase Chain Reaction
      • 8.1.4.1. Digital PCR
      • 8.1.4.2. Quantitative PCR
  • 8.2. Imaging Devices
    • 8.2.1. Computed Tomography
      • 8.2.1.1. Cone Beam CT
      • 8.2.1.2. Multi-Slice CT
    • 8.2.2. Magnetic Resonance Imaging
      • 8.2.2.1. 1.5T Imaging
      • 8.2.2.2. 3T Imaging
    • 8.2.3. Positron Emission Tomography
      • 8.2.3.1. PET/CT Hybrid
      • 8.2.3.2. PET/MRI Hybrid
    • 8.2.4. Ultrasound Imaging
      • 8.2.4.1. 2D Imaging
      • 8.2.4.2. 3D/4D Imaging
    • 8.2.5. X-Ray Imaging
      • 8.2.5.1. Computed Radiography
      • 8.2.5.2. Digital Radiography
  • 8.3. Monitoring Devices
    • 8.3.1. Biosensors
    • 8.3.2. Wearable Devices
  • 8.4. Surgical Devices
    • 8.4.1. Cryosurgery
    • 8.4.2. Laparoscopic Surgery
    • 8.4.3. Robotic Surgery
  • 8.5. Therapeutic Devices
    • 8.5.1. Drug Delivery Devices
    • 8.5.2. Radiation Therapy Devices
      • 8.5.2.1. Brachytherapy Systems
      • 8.5.2.2. Linear Accelerators
      • 8.5.2.3. Proton Therapy Systems

9. Next-Generation Oncology Devices & Solutions Market, by Technology

  • 9.1. Artificial Intelligence
    • 9.1.1. Data Analytics
    • 9.1.2. Deep Learning
    • 9.1.3. Machine Learning
  • 9.2. Bioinformatics
    • 9.2.1. NGS Data Analysis
    • 9.2.2. Proteomics Data Analysis
  • 9.3. Digital Pathology
    • 9.3.1. Image Analysis Software
    • 9.3.2. Whole Slide Imaging
  • 9.4. Nanotechnology
    • 9.4.1. Nanocarriers
    • 9.4.2. Nanodiagnostics
  • 9.5. Robotics
    • 9.5.1. Biopsy Robotics
    • 9.5.2. Surgical Robotics

10. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Oncology Devices & Solutions Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Next-Generation Oncology Devices & Solutions Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Next-Generation Oncology Devices & Solutions Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Next-Generation Oncology Devices & Solutions Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Next-Generation Oncology Devices & Solutions Market

16. China Next-Generation Oncology Devices & Solutions Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Brainlab
  • 17.9. Danaher Corporation
  • 17.10. Exact Sciences Corp.
  • 17.11. F. Hoffmann-La Roche Ltd.
  • 17.12. GE HealthCare Technologies, Inc.
  • 17.13. Guardant Health Inc.
  • 17.14. Hologic, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Johnson & Johnson Services Inc.
  • 17.17. Merck & Co., Inc.
  • 17.18. Myriad Genetics, Inc.
  • 17.19. NanoString Technologies, Inc.
  • 17.20. Natera, Inc.
  • 17.21. NeoGenomics, Inc.
  • 17.22. Novartis AG
  • 17.23. Paige.AI, Inc.
  • 17.24. PerkinElmer, Inc.
  • 17.25. QIAGEN N.V.
  • 17.26. Quest Diagnostics Incorporated
  • 17.27. Royal Philips
  • 17.28. Siemens AG
  • 17.29. Sysmex Corporation
  • 17.30. Takara Bio USA, Inc.
  • 17.31. Thermo Fisher Scientific Inc.
  • 17.32. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LINEAR ACCELERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTON THERAPY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NGS DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROTEOMICS DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE SLIDE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOCARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANODIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOPSY ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL ROBOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NANOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTICS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 20